Now that you’ve concluded your brand’s 2020 business plans and finalized budgets, did senior management express confidence in your health system/integrated delivery network (IDN) strategy and performance?
Cancer treatment has been transformed by therapeutic innovation based on improved understanding of disease biology and advances in precision medicine and immuno-oncology. This exciting time of advancement has achieved unprecedented improvements in survival and reduced side-effects compared to chemotherapy but also introduced skyrocketing cost challenges.
Branded pharmaceutical market access may seem challenging in long-term care (LTC) if you only consider the higher drug cost without factoring in the potential total cost of care offset associated with an evidenced-based therapeutic option.
Discover what good looks like in a Pharma-IDN EHR collaboration and how to ensure your key account management team has everything they need for success.
Why a pharma company’s plans to achieve collaborations with health systems may not be meeting expectations. Why some pharma programs may not have achieved national uptake. And why it’s up to senior leadership to find the fix.